Statements regarding the Company's cash runway do not indicate when or if the Company may access the capital markets. Any of the foregoing risks could materially and adversely affect iTeos' business, results of operations and the trading price of iTeos' common stock. We caution investors not to place undue reliance on the forward-looking statements contained in this press release. iTeos does not undertake any obligation to publicly update its forward-looking statements other than as required by law. CONTACT: For further information, please contact: Investor Contact: Carl Mauch iTeos Therapeutics, Inc. ... Media Contact: ... MENAFN28042025004107003653ID1109483033